Reduced proliferation[80-82,84,86], apoptosis[81,83,85,86], autophagy[83], increased sensitivity to anti-cancer drug[81,82], no effect on tumour size[82], inhibition of survivin[81], activation of BAX, Caspase 9, PARP, p27, and Rb[81], cell cycle arrest[81] at G1 phase[82,86], inhibition of stemness marker CD133[81], increased expression of astrocytic marker GFAP[81], increased ROS level[83], reduced viability[84], reduced wound healing[84], altered cell and spheroid morphology[84,85], reduced colony formation efficiency[85]. Here, BIRC5 is linked to cancer.